companyprofile
Actions
Jamjoom Pharmaceuticals Factory Co.
- Main Market
- Pharma, Biotech & Life Science
Stats Overview
-
Prev. Close 178.80
-
Open 179.00
-
High 181.60
-
Low 176.40
-
No. of Trades 1,675
-
Avg. Trade size* 60
-
Volume Traded 100,419
-
Value Traded (SAR) 17,948,719.60
Performance
- *Average Trade Size = Cumulative / # of Trades
- **52 Week Price Change = (Current Price - Price year ago) / Price year ago x 100
- Historical prices & volume traded data are adjusted to account for all corporate actions.
- MO: Market Order
Trade Updates
Last Trade
Best Bid
Best Offer
52 WEEK
PERFORMANCE
Compare Selected
Select a Maximum of 5 Companies
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions
AnnouncmentandCorporateAction
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Announcements
Corporate Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Dividends
| Announced Date | Eligibility Date | Distribution Date | Distribution Way | Dividend Amount |
|---|---|---|---|---|
| 06/08/2024 | 15/08/2024 | 25/08/2024 | Account Transfer | 1.60 |
| 04/04/2024 | 04/06/2024 | 13/06/2024 | Account Transfer | 1.50 |
| 10/08/2023 | 20/08/2023 | 03/09/2023 | Account Transfer | 1.00 |
CompanyProfilev2Financials
Actions
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Financials
- FINANCIAL INFORMATION
- FINANCIAL STATEMENTS AND REPORTS
- Annually
- Quarterly
| Balance Sheet | 2023-12-31 | |||
|---|---|---|---|---|
| Total Assets |
1,654,166
|
- | - | - |
| Total Liabilities |
249,837
|
- | - | - |
| Total Shareholders Equity (After Deducting the Minority Equity) |
1,404,329
|
- | - | - |
| Total Liabilities and Shareholders Equity |
1,654,166
|
- | - | - |
| Statement of Income | 2023-12-31 | |||
| Total Revenue (Sales/Operating) |
1,100,819
|
- | - | - |
| Net Profit (Loss) before Zakat and Tax |
315,799
|
- | - | - |
| Zakat and Income Tax |
-23,399
|
- | - | - |
| Net Profit (Loss) after Zakat and Tax |
292,400
|
- | - | - |
| Total Comprehensive Income |
258,066
|
- | - | - |
| Profit (Loss) per Share |
4.18
|
- | - | - |
| Cash Flows | 2023-12-31 | |||
| Net Cash From Operating Activities |
296,028
|
- | - | - |
| Net Cash From Investing Activities |
-77,442
|
- | - | - |
| Net Cash From Financing Activities |
-70,347
|
- | - | - |
| Cash and Cash Equivalents, Beginning of the Period |
141,182
|
- | - | - |
| Cash and Cash Equivalents, End of the Period |
284,277
|
- | - | - |
| All Figures in | Thousands | |||
| All Currency In | SAR | |||
| Last Update Date | 2024-04-01 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
| Balance Sheet | 2024-06-30 | 2024-03-31 | 2023-09-30 | |
|---|---|---|---|---|
| Total Assets |
1,814,658.38
|
1,760,896.94
|
1,658,857
|
|
| Total Liabilities |
351,434.86
|
299,401.64
|
297,559
|
|
| Total Shareholders Equity (After Deducting the Minority Equity) |
1,463,223.52
|
1,461,495.3
|
1,361,298
|
|
| Total Liabilities and Shareholders Equity |
1,814,658.38
|
1,760,896.94
|
1,658,857
|
|
| Statement of Income | 2024-06-30 | 2024-03-31 | 2023-09-30 | |
| Total Revenue (Sales/Operating) |
345,735.7
|
385,461.64
|
292,613
|
|
| Net Profit (Loss) before Zakat and Tax |
110,193.72
|
112,733.14
|
83,858
|
|
| Zakat and Income Tax |
-3,240.49
|
-9,763.75
|
-6,611
|
|
| Net Profit (Loss) after Zakat and Tax |
106,953.23
|
102,969.4
|
77,247
|
|
| Total Comprehensive Income |
106,728.22
|
57,166.33
|
76,433
|
|
| Profit (Loss) per Share |
1.53
|
1.47
|
1.1
|
|
| Cash Flows | 2024-06-30 | 2024-03-31 | 2023-09-30 | |
| Net Cash From Operating Activities |
22,675.1
|
-46,896.61
|
95,843
|
|
| Net Cash From Investing Activities |
-41,630.57
|
-21,324.79
|
-68,686
|
|
| Net Cash From Financing Activities |
105,266.68
|
-234.02
|
-70,263
|
|
| Cash and Cash Equivalents, Beginning of the Period |
284,276.77
|
284,276.77
|
141,182
|
|
| Cash and Cash Equivalents, End of the Period |
156,255.19
|
210,477.38
|
93,191
|
|
| All Figures in | Thousands | Thousands | Thousands | |
| All Currency In | SAR | SAR | SAR | |
| Last Update Date | 2024-08-22 | 2024-05-19 | 2023-11-12 |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
- Announcements & Corporate Actions
- Dividends
- Financials
- Shareholding
- Peer Comparison
- Company Profile
Company Profile
Company overview
The Company is primarily focused on developing, manufacturing, and distributing a wide range of generic pharmaceuticals, cosmetics, and consumer healthcare products. Its products are supplied and marketed in over 36 countries spanning across the GCC, Levant, North Africa, and other regions, the company is committed to providing high-quality products to its customers. Its extensive portfolio of offerings and its widespread distribution network make it a leading player in the industry
Company History
Jamjoom Pharmaceuticals Factory Company was established as a branch of Abdullatif Mohammed Salah Jamjoom and Brothers Company under commercial registration no. 4030106218 dated 16/04/1415H (corresponding to 22/09/1994G) issued in Jeddah, KSA. On 12/09/1425H (corresponding to 26/10/2004G), the branch of Abdullatif Mohammed Salah Jamjoom and Brothers Company was converted into a limited liability company under the name of Jamjoom Pharmaceuticals Factory Company Limited under commercial registration no. 4030154596 dated 18/02/1426H (corresponding to 28/03/2005G) with a capital of twenty million Saudi Riyals (SAR 20,000,000). On 17/11/1428H (corresponding to 27/11/2007G), the General Assembly approved an increase of the Company''s capital from twenty million Saudi Riyals (SAR 20,000,000) to sixty million Saudi Riyals (SAR 60,000,000) divided into sixty thousand (60,000) cash shares of equal value of one thousand Saudi Riyals (SAR 1,000) per share, through the capitalization of forty million Saudi Riyals (SAR 40,000,000) from the retained earnings account. On 09/06/1433H (corresponding to 30/04/2012G), the General Assembly approved an increase of the Company''s capital from sixty million Saudi Riyals (SAR 60,000,000) to one hundred million Saudi Riyals (SAR 100,000,000) , divided into one hundred thousand (100,000) cash shares of equal value of one thousand Saudi Riyals (SAR 1,000) per share, through the capitalization of forty million Saudi Riyals (SAR 40,000,000) from the retained earnings account. On 09/11/1434H, (corresponding to 21/01/2013G), the Company was converted from a limited liability company to a (closed) joint-stock company pursuant to a ministerial resolution no. 202/s, dated 19/08/1435H (corresponding to 17/06/2014G) approving the publication of the Company''s conversion. Upon conversion, the Company''s share capital was one hundred million Saudi Riyals (SAR 100,000,000), divided into ten million (10,000,000) Shares with a fully paid-up nominal value of SAR 10 per share. On 18/12/1443H (corresponding to 17/07/2022G), the General Assembly approved an increase of the Company''s capital from one hundred million Saudi Riyals (SAR 100,000,000) to seven hundred million Saudi Riyals (SAR 700,000,000), divided into seventy million (70,000,000) Shares with a fully-paid up nominal value of SAR 10 consisting of ten million ordinary shares paid in-kind and sixty million (60,000,000) ordinary shares paid in cash, per Share through the capitalization of six hundred million Saudi Riyals (SAR 600,000,000) from the retained earnings account.
Company Bylaws
Equity Profile
- Authorized Capital (SAR) 700,000,000
- Issued Shares 70,000,000
- Paid Capital (SAR) 700,000,000
- Par Value/Share 10
- Paid Up Value/Share 10
Last Update :2023-06-20
Investment limits
There are no investment limits on the company's shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on Company's bylaw and the issued Instructions by related regulators and supervisory authorities.
- Company Details
- BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
Investor Relations
Contact Name:
Muhammad Bin Khalid Khan
Company Address:
P.O. Box # 6267, Jeddah-21442, Kingdom of Saudi Arabia
Contact Details:
Telephone:
+966 12 614 0099
Fax
: +966 12 614 0088
Email
: IR@Jamjoompharma.com
Company Website:
| Name Of Subsidiary | Percentage Of Property | Main Business | Location Of Operation | Country Of Operation |
|---|---|---|---|---|
| Al-Jamjoom Pharma for Pharmaceutical Industries | 100.00% | Establishing and operating a factory for the manufacture of human and veterinary medicines, medical preparations, and packaging requirements of all kinds, as well as manufacturing for third parties and by third parties. | Egypt | Egypt |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.